NOTIFICATION

Corrigendum

The following communication by Japan is being circulated in accordance with Article 10.4.

Under item 9, Proposed date of adoption and entry into force, the information should be amended to read:

(1) Assistance, advice and guidance in developing orphan drugs; extension of the re-examination period; priority examination effective from October, 1993.

(2) Delegation of licensing authority effective from April, 1995.

(3) Others

Incorporation of GMP programme as a prerequisite for license; allocation of a half amount of fees for a license belonging to the authority of Minister to prefectural governments; setting up of new fees for licenses of additional items, New business other than orphan drugs in the Adverse Drug Reaction Sufferings Relief and Research Promotion Fund effective from April, 1994.